- |||||||||| Cholebine (colestilan) / Mitsubishi Tanabe
Review, Journal: Bile Acid Sequestrants Based on Natural and Synthetic Gels. (Pubmed Central) - Jun 27, 2023
Focus is given to the understanding of the relationships between the chemical structure of these cross-linked polymers and their potential to bind bile salts. The synthetic pathways used in obtaining BASs and their in vitro and in vivo hypolipidemic activities are also introduced.
- |||||||||| Cholebine (colestilan) / Mitsubishi Tanabe
Journal: Usefulness of colestimide for diarrhea in postoperative Crohn's disease. (Pubmed Central) - Aug 6, 2022
In the global clinical judgment, 13 and 4 patients in the ileocecal and non-ileocecal resection groups, respectively, were judged as "effective," with an overall efficacy rate of 70.8%. Colestimide is effective for diarrhea in patients with postoperative CD, especially after ileocecal resection.
- |||||||||| Cholebine (colestilan) / Mitsubishi Tanabe, Repatha (evolocumab) / Amgen, Astellas
Journal: Clinical and genetic features of sitosterolemia in Japan. (Pubmed Central) - Apr 20, 2022
Colestimide is effective for diarrhea in patients with postoperative CD, especially after ileocecal resection. We are providing a demographic overview of the clinical and genetic backgrounds of Japanese patients with sitosterolemia.
- |||||||||| Cholebine (colestilan) / Mitsubishi Tanabe
Journal: A case of COVID-19 diarrhea relieved by bile acid sequestrant administration. (Pubmed Central) - Apr 1, 2022
The oral administration of a bile acid sequestrant, colestimide, improved his diarrhea quickly...It decreases bile acid absorption at the distal ileum and increases colonic delivery of bile acids, resulting in bile acid diarrhea. In summary, the clinical course of the case presented in this report suggests that bile acid diarrhea is a possible mechanism of watery diarrhea observed in patients with coronavirus disease 2019.
- |||||||||| Review, Journal: Phosphate binders in chronic kidney disease: an updated narrative review of recent data. (Pubmed Central) - Aug 20, 2021
For this narrative review a PubMed searched was undertaken to identify new publications on phosphate binders that had been published between January 2015 and July 2019. The present review summarizes this most recent information on dietary measures and their problems in treating hyperphosphatemia in CKD patients, overall effects of phosphate binders on cardiovascular mortality and morbidity, adherence to phosphate binder therapy as well as new data on specific aspects of the various phosphate binders on the market: calcium-containing phosphate binders, polymeric phosphate binders (sevelamer, bixalomer, colestilan), magnesium-containing phosphate binders, lanthanum carbonate, ferric citrate, sucroferric oxyhydroxide, and new compounds in development, in particular drugs targeting intestinal phosphate transporters.
- |||||||||| Cholebine (colestilan) / Mitsubishi Tanabe
Clinical, Journal: Comparative Efficacy and Safety of Phosphate Binders in Hyperphosphatemia Patients With Chronic Kidney Disease. (Pubmed Central) - Nov 15, 2019
The present review summarizes this most recent information on dietary measures and their problems in treating hyperphosphatemia in CKD patients, overall effects of phosphate binders on cardiovascular mortality and morbidity, adherence to phosphate binder therapy as well as new data on specific aspects of the various phosphate binders on the market: calcium-containing phosphate binders, polymeric phosphate binders (sevelamer, bixalomer, colestilan), magnesium-containing phosphate binders, lanthanum carbonate, ferric citrate, sucroferric oxyhydroxide, and new compounds in development, in particular drugs targeting intestinal phosphate transporters. Iron-based phosphate-binding agents were the preferable agents when considering efficacy and safety simultaneously.
- |||||||||| Cholebine (colestilan) / Mitsubishi Tanabe
Enrollment change, Trial termination: Safety and Tolerability Study of MCI-196 (clinicaltrials.gov) - Jun 11, 2015
P3, N=4, Terminated,
Iron-based phosphate-binding agents were the preferable agents when considering efficacy and safety simultaneously. N=45 --> 4 | Recruiting --> Terminated; This study has been terminated because of insufficient patient recruitment.
- |||||||||| Cholebine (colestilan) / Mitsubishi Tanabe
Enrollment change, Trial termination, Trial primary completion date: Long-term Extension Study of MCI-196 (clinicaltrials.gov) - Jun 11, 2015
P3, N=6, Terminated,
N=45 --> 4 | Recruiting --> Terminated; This study has been terminated because of insufficient patient recruitment. N=100 --> 6 | Recruiting --> Terminated | Trial primary completion date: Mar 2015 --> Dec 2014; This study has been terminated because of insufficient patient recruitment.
- |||||||||| Cholebine (colestilan) / Mitsubishi Tanabe
Enrollment change, Trial termination: Dose-finding Study of MCI-196 (clinicaltrials.gov) - Jun 11, 2015
P3, N=10, Terminated,
N=100 --> 6 | Recruiting --> Terminated | Trial primary completion date: Mar 2015 --> Dec 2014; This study has been terminated because of insufficient patient recruitment. N=140 --> 10 | Recruiting --> Terminated; This study has been terminated because of insufficient patient recruitment.
- |||||||||| Cholebine (colestilan) / Mitsubishi Tanabe
Trial initiation date: Dose-finding Study of MCI-196 (clinicaltrials.gov) - Apr 12, 2014
P3, N=140, Recruiting,
N=140 --> 10 | Recruiting --> Terminated; This study has been terminated because of insufficient patient recruitment. Initiation date: May 2013 --> Apr 2014
- |||||||||| Cholebine (colestilan) / Mitsubishi Tanabe
Trial initiation date: Safety and Tolerability Study of MCI-196 (clinicaltrials.gov) - Oct 8, 2013
P3, N=45, Recruiting,
Recruiting --> Completed Initiation date: Mar 2013 --> Aug 2013
- |||||||||| Cholebine (colestilan) / Mitsubishi Tanabe
Trial initiation date: Long-term Extension Study of MCI-196 (clinicaltrials.gov) - Oct 8, 2013
P3, N=100, Recruiting,
Initiation date: Mar 2013 --> Aug 2013 Initiation date: May 2013 --> Aug 2013
- |||||||||| Cholebine (colestilan) / Mitsubishi Tanabe
Enrollment open: Safety and Tolerability Study of MCI-196 (clinicaltrials.gov) - Oct 8, 2013
P3, N=45, Recruiting,
Initiation date: May 2013 --> Aug 2013 Not yet recruiting --> Recruiting
- |||||||||| Cholebine (colestilan) / Mitsubishi Tanabe
Enrollment open: Long-term Extension Study of MCI-196 (clinicaltrials.gov) - Oct 8, 2013
P3, N=100, Recruiting,
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Cholebine (colestilan) / Mitsubishi Tanabe
Enrollment open: Dose-finding Study of MCI-196 (clinicaltrials.gov) - Oct 8, 2013
P3, N=140, Recruiting,
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Cholebine (colestilan) / Mitsubishi Tanabe
New P3 trial: Dose-finding Study of MCI-196 (clinicaltrials.gov) - Mar 18, 2013
P3, N=140, Recruiting,
|
